Listeriosis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major listeriosis markets are expected to exhibit a CAGR of 4.08% during 2024-2034.
The listeriosis market has been comprehensively analyzed in IMARC's new report titled "Listeriosis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Listeriosis refers to a bacterial infection caused by the pathogen Listeria monocytogenes. This bacterium is commonly found in soil, water, and certain animals, making it a potential contaminant in various types of food. The infection primarily affects individuals with weakened immune systems, pregnant women, newborns, and the elderly. The symptoms of listeriosis can vary and often include fever, muscle aches, nausea, diarrhea, and gastrointestinal distress. In more severe cases, the disorder can lead to complications, such as septicemia, meningitis, and even death. Pregnant women suffering from the ailment can also experience miscarriages, stillbirths, or numerous other adverse outcomes for their unborn babies. The diagnosis of listeriosis is typically based on a combination of clinical findings and laboratory investigations. A healthcare provider might also perform blood or cerebrospinal fluid cultures to isolate the Listeria bacteria and confirm the diagnosis. Early detection of the disease is crucial to initiate timely treatment for patients.
The escalating incidences of bacterial infection caused by the consumption of contaminated food, particularly dairy products, deli meats, and unwashed vegetables, are primarily driving the listeriosis market. In addition to this, the inflating utilization of effective antibiotics, such as ampicillin and gentamicin, along with advanced medical interventions like intravenous fluid administration and supportive care, is also creating a positive outlook for the market. Moreover, the widespread adoption of stringent food safety regulations and practices to curb the spread of the infection among individuals is further bolstering the market growth. Apart from this, the rising usage of surveillance systems and diagnostic technologies for early detection and swift management of listeriosis cases is acting as another significant growth-inducing factor. These measures aid in the prompt identification of outbreaks, enabling timely interventions, and preventing the widespread transmission of the bacteria. Additionally, the emerging popularity of public health campaigns that emphasize the significance of safe food preparation and storage practices is also augmenting the market growth. Furthermore, the increasing application of bacteriophage therapy, which involves using naturally occurring viruses that specifically target and eliminate certain pathogenic bacteria, thereby reducing the development of the disease, is expected to drive the listeriosis market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the listeriosis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for listeriosis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the listeriosis market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the listeriosis market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the listeriosis market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current listeriosis marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Key Questions Answered in this Report:
Market Insights
How has the listeriosis market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the listeriosis market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the listeriosis market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of listeriosis across the seven major markets?
What is the number of prevalent cases (2018-2034) of listeriosis by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of listeriosis by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with listeriosis across the seven major markets?
What is the size of the listeriosis patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of listeriosis?
What will be the growth rate of patients across the seven major markets?
Listeriosis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for listeriosis drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the listeriosis market?
What are the key regulatory events related to the listeriosis market?
What is the structure of clinical trial landscape by status related to the listeriosis market?
What is the structure of clinical trial landscape by phase related to the listeriosis market?
What is the structure of clinical trial landscape by route of administration related to the listeriosis market?
The listeriosis market has been comprehensively analyzed in IMARC's new report titled "Listeriosis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Listeriosis refers to a bacterial infection caused by the pathogen Listeria monocytogenes. This bacterium is commonly found in soil, water, and certain animals, making it a potential contaminant in various types of food. The infection primarily affects individuals with weakened immune systems, pregnant women, newborns, and the elderly. The symptoms of listeriosis can vary and often include fever, muscle aches, nausea, diarrhea, and gastrointestinal distress. In more severe cases, the disorder can lead to complications, such as septicemia, meningitis, and even death. Pregnant women suffering from the ailment can also experience miscarriages, stillbirths, or numerous other adverse outcomes for their unborn babies. The diagnosis of listeriosis is typically based on a combination of clinical findings and laboratory investigations. A healthcare provider might also perform blood or cerebrospinal fluid cultures to isolate the Listeria bacteria and confirm the diagnosis. Early detection of the disease is crucial to initiate timely treatment for patients.
The escalating incidences of bacterial infection caused by the consumption of contaminated food, particularly dairy products, deli meats, and unwashed vegetables, are primarily driving the listeriosis market. In addition to this, the inflating utilization of effective antibiotics, such as ampicillin and gentamicin, along with advanced medical interventions like intravenous fluid administration and supportive care, is also creating a positive outlook for the market. Moreover, the widespread adoption of stringent food safety regulations and practices to curb the spread of the infection among individuals is further bolstering the market growth. Apart from this, the rising usage of surveillance systems and diagnostic technologies for early detection and swift management of listeriosis cases is acting as another significant growth-inducing factor. These measures aid in the prompt identification of outbreaks, enabling timely interventions, and preventing the widespread transmission of the bacteria. Additionally, the emerging popularity of public health campaigns that emphasize the significance of safe food preparation and storage practices is also augmenting the market growth. Furthermore, the increasing application of bacteriophage therapy, which involves using naturally occurring viruses that specifically target and eliminate certain pathogenic bacteria, thereby reducing the development of the disease, is expected to drive the listeriosis market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the listeriosis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for listeriosis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the listeriosis market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the listeriosis market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the listeriosis market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current listeriosis marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Key Questions Answered in this Report:
Market Insights
How has the listeriosis market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the listeriosis market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the listeriosis market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of listeriosis across the seven major markets?
What is the number of prevalent cases (2018-2034) of listeriosis by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of listeriosis by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with listeriosis across the seven major markets?
What is the size of the listeriosis patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of listeriosis?
What will be the growth rate of patients across the seven major markets?
Listeriosis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for listeriosis drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the listeriosis market?
What are the key regulatory events related to the listeriosis market?
What is the structure of clinical trial landscape by status related to the listeriosis market?
What is the structure of clinical trial landscape by phase related to the listeriosis market?
What is the structure of clinical trial landscape by route of administration related to the listeriosis market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 LISTERIOSIS - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 LISTERIOSIS - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 LISTERIOSIS - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 LISTERIOSIS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 LISTERIOSIS - UNMET NEEDS
10 LISTERIOSIS - KEY ENDPOINTS OF TREATMENT
11 LISTERIOSIS - MARKETED PRODUCTS
11.1 List of Listeriosis Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 LISTERIOSIS - PIPELINE DRUGS
12.1 List of Listeriosis Pipeline Drugs Across the Top 7 Markets
12.1.1 Drug Name – Company Name
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the complete list of pipeline drugs has been provided in the report.
13. LISTERIOSIS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. LISTERIOSIS – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 LISTERIOSIS - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Listeriosis - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Listeriosis - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Listeriosis - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Listeriosis - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Listeriosis - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Listeriosis - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Listeriosis - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Listeriosis - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Listeriosis - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Listeriosis - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Listeriosis - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Listeriosis - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Listeriosis - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Listeriosis - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Listeriosis - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Listeriosis - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Listeriosis - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Listeriosis - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Listeriosis - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Listeriosis - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Listeriosis - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Listeriosis - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Listeriosis - Access and Reimbursement Overview
16 LISTERIOSIS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 LISTERIOSIS MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 LISTERIOSIS MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 LISTERIOSIS - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 LISTERIOSIS - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 LISTERIOSIS - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 LISTERIOSIS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 LISTERIOSIS - UNMET NEEDS
10 LISTERIOSIS - KEY ENDPOINTS OF TREATMENT
11 LISTERIOSIS - MARKETED PRODUCTS
11.1 List of Listeriosis Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 LISTERIOSIS - PIPELINE DRUGS
12.1 List of Listeriosis Pipeline Drugs Across the Top 7 Markets
12.1.1 Drug Name – Company Name
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the complete list of pipeline drugs has been provided in the report.
13. LISTERIOSIS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. LISTERIOSIS – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 LISTERIOSIS - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Listeriosis - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Listeriosis - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Listeriosis - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Listeriosis - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Listeriosis - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Listeriosis - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Listeriosis - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Listeriosis - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Listeriosis - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Listeriosis - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Listeriosis - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Listeriosis - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Listeriosis - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Listeriosis - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Listeriosis - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Listeriosis - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Listeriosis - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Listeriosis - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Listeriosis - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Listeriosis - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Listeriosis - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Listeriosis - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Listeriosis - Access and Reimbursement Overview
16 LISTERIOSIS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 LISTERIOSIS MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 LISTERIOSIS MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
